Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced the successful completion of its human clinical study GLP-1-H25-5. The study compared oral capsules of DehydraTECH-liraglutide to the injected Saxenda®-branded liraglutide. Partial results from the study are now available and indicate a pronounced reduction in adverse events associated with the oral DehydraTECH-liraglutide. Lexaria has demonstrated reductions in adverse events across all three major GLP-1 drugs: liraglutide, semaglutide, and tirzepatide, in distinct clinical human studies. Currently, Lexaria is seeking a pharmaceutical partner to support an FDA-registered oral alternative to the existing injectable GLP-1 brands.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。